Merck Breaks Ground on $1 Billion Biologics Center in Wilmington, Delaware to Support U.S. Production of Keytruda

Gelonghui April 29 | MSD announced the groundbreaking of a $1 billion biologics center in Wilmington, Delaware, USA. The center will include laboratories, production, and warehousing capabilities to support the launch and commercial manufacturing of next-generation biologics and therapies. MSD stated that the goal is to establish it as the future U.S. production base for Keytruda to serve American patients.